my cart
  • log-in
  • applications / products

    Applications

    • Drug Discovery & Development
    • Cell Banks for Bioassays
    • Potency & QC Lot Release
    • Detect Neutralizing Abs
    • Cytotoxicity Assays
    • Target Engagement
    • Translocation Assays
    • Targeted Protein Degradation
    • Signaling Pathway Reporters
    • Pharmacotrafficking Assays
    • Do-It-Yourself Assays
    • Therapeutic/Disease Area
    • Custom Development Capabilities

    Products

    • Cells & Cell Lines
    • Assay Ready Kits
    • Bioassay Kits
    • eXpress Kits
    • Frozen Cells
    • Membrane Preps
    • Proteins & Kinases
    • Cell Culture Reagents
    • Detection Reagents
    • Biochemical Assays
    • Control Ligands & Inhibitors
  • targets
    • A-Z List of Target List
    • GPCRs
    • Kinases
    • Checkpoint Receptors
    • Ion Channels
    • Cytokines & Interleukins
    • Signaling Pathways
    • Nuclear Proteins
    • Epigenetics Proteins
  • technologies / platforms
    • Enzyme Fragment Complementation
    • Human Primary Cell Screening
    • Competition Binding Platform
  • tools / resources

    Document Resource Library

    • Flyers & Brochure
    • User Manuals & Protocols
    • White Papers & Applications
    • Scientific Posters
    • Presentations

    Webinars

    Knowledge-Based Videos

    Blogs

    Publications & References

    CRO Certification

    Reagent Calculators

    Instrument Compatibility

  • services
  • Contact Us
    • Customer & Technical Support
    • Submit an Order
    • Technical Resources
    • Literature & Email Signup
    • Legal & Policies
    • Locations
    • Distributors
    • Procurement Partners
  • about us
    • Company
    • Contact Us
    • Careers
    • Announcements
    • Events
Search Product
Contact a Specialist
PathHunter® Jurkat CD28 Signaling Cell Line

/products/cell-line/jurkat-cd28-signaling-cell-line-93-1126c19
The Engineered CD80 Variant Fusion Therapeutic Davoceticept Combines Checkpoint Antagonism with Conditional CD28 Costimulation for Anti-Tumor Immunity
Despite the recent clinical success of T cell checkpoint inhibition targeting the CTLA-4 and PD-1 pathways, many patients either fail to achieve objective responses or they develop resistance to therapy. In some cases, poor responses to checkpoint blockade have been linked t...
/tools-resources/publications-references/publications/the-engineered-cd80-variant-fusion-therapeutic-dav 5/24/2022 11:38:03 PM
[SLAS 2017] CAR-T Cell Screening in Tumor Spheroids Using Corning Spheroid Microplates
Chimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown promise to affect complete remission in patients with B-cell malignancies. However, applying this approach to target solid tumors has r...
/tools-resources/document-resource-library/documents/slas-2017-car-t-cell-screening-in-tumor-spheroids-using-corning-spheroid-microplates 2/9/2017 4:53:25 PM
[User Manual] PathHunter® Checkpoint Signaling Assay - Immunoglobulin Superfamily (IgSF)
The PathHunter Checkpoint Receptor Signaling Assay is a simple, highly specific assay to enable discovery and development of small molecule and biologic drugs targeting immune checkpoint receptors, belonging to the Immunoglobulin Superfamily (IgSF), such as PD-1, CD28 and ICO...
/tools-resources/document-resource-library/documents/user-manual-pathhunter®-checkpoint-signaling-ass 12/4/2015 4:41:54 PM
Checkpoint Receptors
Applications Assay Principle Assay Highlights Advantages of Checkpoint Assays PathHunter checkpoint assays are MOA-reflective assays for quantifying a functional response as a result of direct ligand binding to its checkpoint receptor.  These cell-based assays enable rapid s...
/targets/checkpoint-assays 4/29/2020 4:06:29 PM
[DOT 2017] Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have prove...
/tools-resources/document-resource-library/documents/dot-2017-novel,-improved-cell-based-assays-to-enable-immunotherapy-drug-development-for-checkpoint 9/22/2017 6:37:39 PM
[ELRIG 2017] Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have prove...
/tools-resources/document-resource-library/documents/elrig-2017-novel,-improved-cell-based-assays-to-enable-immunotherapy-drug-development-for-checkpoi 9/26/2017 11:24:43 PM
[BEBPA 2017] Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have prov...
/tools-resources/document-resource-library/documents/bebpa-2017-checkpoint-receptor-poster 9/27/2017 5:50:09 PM
Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells.
PGD2, produced by mast cells, has been detected in high concentrations at sites of allergic inflammation. It can stimulate vascular and other inflammatory responses by interaction with D prostanoid receptor (DP) and chemoattractant receptor-like molecule expressed on Th2 cells...
/tools-resources/publications-references/publications/prostaglandin-d2-causes-preferential-induction-of 10/3/2012 5:51:07 PM
+ sitemap © 2020 Eurofins DiscoverX Products. All rights reserved.
  • Contact Us
  • Legal & Privacy
  • Cookie Notice